Cosimo De Nunzio1, Riccardo Lombardo2, Giorgia Tema2, Andrea Tubaro2. 1. Department of Urology, Sant'Andrea Hospital, "La Sapienza" University, Via di Grottarossa 1035, 00189, Rome, Italy. cosimodenunzio@virgilio.it. 2. Department of Urology, Sant'Andrea Hospital, "La Sapienza" University, Via di Grottarossa 1035, 00189, Rome, Italy.
Abstract
PURPOSE OF REVIEW: In the past years, the relationship between lower urinary tract symptoms and erectile dysfunction has been widely explored. The aim of our systematic review is to summarize the published evidence over the past year on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). RECENT FINDINGS: Recent data support the relationship between LUTS and ED in Eastern Europe and in Asia. The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence. LUTS and ED are prevalent conditions in men over 50; epidemiologically, the relationship between both conditions has been confirmed all over the world. PDE5i alone or in combination with alpha blockers can be considered the gold standard for the treatment of young patients with storage symptoms and concomitant ED. In clinical research, a better understanding of the molecular pathways behind this association may also help to identify new possible targets and develop novel therapeutic approaches to manage both disorders; the identification of new biomarkers of both disorders is also compulsory in this area.
PURPOSE OF REVIEW: In the past years, the relationship between lower urinary tract symptoms and erectile dysfunction has been widely explored. The aim of our systematic review is to summarize the published evidence over the past year on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). RECENT FINDINGS: Recent data support the relationship between LUTS and ED in Eastern Europe and in Asia. The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence. LUTS and ED are prevalent conditions in men over 50; epidemiologically, the relationship between both conditions has been confirmed all over the world. PDE5i alone or in combination with alpha blockers can be considered the gold standard for the treatment of young patients with storage symptoms and concomitant ED. In clinical research, a better understanding of the molecular pathways behind this association may also help to identify new possible targets and develop novel therapeutic approaches to manage both disorders; the identification of new biomarkers of both disorders is also compulsory in this area.
Authors: D Francomano; A Ilacqua; A Cortese; G Tartaglia; A Lenzi; M Inghilleri; A Aversa Journal: J Endocrinol Invest Date: 2016-10-17 Impact factor: 4.256
Authors: Aldo E Calogero; Giovanni Burgio; Rosita A Condorelli; Rossella Cannarella; Sandro La Vignera Journal: Aging Male Date: 2018-01-27 Impact factor: 5.892
Authors: Sean P Elliott; Mittul Gulati; David J Pasta; G Mark Spitalny; Christopher J Kane; Rita Yee; Tom F Lue Journal: Urology Date: 2004-06 Impact factor: 2.649
Authors: Jason Gandhi; Steven J Weissbart; Noel L Smith; Steven A Kaplan; Gautam Dagur; Anna Zumbo; Gargi Joshi; Sardar Ali Khan Journal: Transl Androl Urol Date: 2017-04
Authors: Sigrid Tibaek; Gunvor Gard; Christian Dehlendorff; Helle K Iversen; Fin Biering-Soerensen; Rigmor H Jensen Journal: Am J Mens Health Date: 2017-02-13
Authors: Heiko Yang; Benjamin N Breyer; Eric B Rimm; Edward Giovannucci; Stacy Loeb; Stacey A Kenfield; Scott R Bauer Journal: BJU Int Date: 2022-06-09 Impact factor: 5.969
Authors: Abdullah Gul; Soner Coban; Ali Riza Turkoglu; Muhammet Guzelsoy; Murat Ozturk; Nazim Abdulkadir Kankilic Journal: Prostate Int Date: 2020-05-19